Lenk H - Search Results

1

Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain.

Laub R, Di Giambattista M, Fondu P, Brackmann HH, Lenk H, Saenko EL, Felch M, Scandella D. Laub R, et al. Among authors: lenk h. Thromb Haemost. 1999 Jan;81(1):39-44. Thromb Haemost. 1999. PMID: 9974372

2

Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay.

Klinge J, Auerswald G, Budde U, Klose H, Kreuz W, Lenk H, Scandella D; Paediatric Inhibitor Study Group of the German Society on Thrombosis and Haemostasis. Klinge J, et al. Among authors: lenk h. Haemophilia. 2001 Jan;7(1):26-32. doi: 10.1046/j.1365-2516.2001.00456.x. Haemophilia. 2001. PMID: 11136377

3

German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies.

Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W. Brackmann HH, et al. Among authors: lenk h. Haemophilia. 1999 May;5(3):203-6. doi: 10.1046/j.1365-2516.1999.00311.x. Haemophilia. 1999. PMID: 10444288

4

Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A.

Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM. Gilles JG, et al. Among authors: lenk h. J Clin Invest. 1996 Mar 15;97(6):1382-8. doi: 10.1172/JCI118558. J Clin Invest. 1996. PMID: 8617869 Free PMC article.

5

Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization.

Schneppenheim R, Lenk H, Obser T, Oldenburg J, Oyen F, Schneppenheim S, Schwaab R, Will K, Budde U. Schneppenheim R, et al. Among authors: lenk h. Thromb Haemost. 2004 Jul;92(1):36-41. doi: 10.1160/TH04-02-0084. Thromb Haemost. 2004. PMID: 15213842

6

Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.

von Auer Ch, Oldenburg J, von Depka M, Escuriola-Ettinghausen C, Kurnik K, Lenk H, Scharrer I. von Auer Ch, et al. Among authors: lenk h. Ann N Y Acad Sci. 2005 Jun;1051:498-505. doi: 10.1196/annals.1361.094. Ann N Y Acad Sci. 2005. PMID: 16126990

7

Incidence of infectious and noninfectious side effects in hemophilia patients in the new German Federal States during treatment with cryoprecipitate.

Lenk H, Schneider M. Lenk H, et al. Semin Thromb Hemost. 2002 Apr;28 Suppl 1:51-6. doi: 10.1055/s-2002-30196. Semin Thromb Hemost. 2002. PMID: 12016579 No abstract available.

8

The German Registry of immune tolerance treatment in hemophilia--1999 update.

Lenk H; ITT Study Group. Lenk H, et al. Haematologica. 2000 Oct;85(10 Suppl):45-7. Haematologica. 2000. PMID: 11187870

9

Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.

Astermark J, Voorberg J, Lenk H, DiMichele D, Shapiro A, Tjönnfjord G, Berntorp E. Astermark J, et al. Among authors: lenk h. Haemophilia. 2003 Sep;9(5):567-72. doi: 10.1046/j.1365-2516.2003.00802.x. Haemophilia. 2003. PMID: 14511295

10

Treatment of haemophilia patients in East Germany prior to and after reunification in 1990.

Lenk H. Lenk H. Thromb Res. 2014 Nov;134 Suppl 1:S57-60. doi: 10.1016/j.thromres.2013.10.018. Epub 2014 Apr 16. Thromb Res. 2014. PMID: 24745720 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters